Capital Management, L.P.Abr... Net Worth

The estimated Net Worth of Capital Management, L.P.Abr... is at least $406 Million dollars as of 8 February 2021. Capital Abr owns over 875,147 units of TransMedics stock worth over $377,459,833 and over the last 4 years Capital sold TMDX stock worth over $28,529,792.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital Abr TMDX stock SEC Form 4 insiders trading

Capital has made over 1 trades of the TransMedics stock since 2021, according to the Form 4 filled with the SEC. Most recently Capital sold 875,147 units of TMDX stock worth $28,529,792 on 8 February 2021.

The largest trade Capital's ever made was selling 875,147 units of TransMedics stock on 8 February 2021 worth over $28,529,792. On average, Capital trades about 875,147 units every 0 days since 2021. As of 8 February 2021 Capital still owns at least 2,624,712 units of TransMedics stock.

You can see the complete history of Capital Abr stock trades at the bottom of the page.

Insiders trading at TransMedics

Over the last 6 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein, and James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.

What does TransMedics do?

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Complete history of Capital Abr stock trades at TransMedics

TransMedics executives and stock owners

TransMedics executives and other stock owners filed with the SEC include:

• Waleed Hassanein,
  President, Chief Executive Officer, Director
• Tamer Khayal,
  Chief Commercial Officer
• Dr. Waleed H. Hassanein,
  Founder, MD, CEO, Pres & Director
• Dr. Tamer I. Khayal,
  Chief Commercial Officer
• Stephen Gordon,
  CFO. Treasurer & Sec.
• Stephen Gordon,
  Chief Financial Officer, Treasurer, Secretary
• David Weill,
  Independent Director
• James Tobin,
  Independent Chairman of the Board
• Thomas Gunderson,
  Independent Director
• Edward Basile,
  Independent Director
• Edwin Kania,
  Independent Director
• John Sullivan,
  Vice President - Quality and Engineering
• Miriam Provost,
  Vice President - Global Regulatory Affairs
• Laura Damme,
  Vice President - Clinical Affairs
• John Carey,
  Vice President - Operations
• Susan Goodman,
  VP of HR
• Mark Anderson,
  Sr. Director of Technology Devel.
• Ike Okonkwo,
  VP of Fin. & Accounting
• John F. Carey,
  VP of Operations
• Therapeutics Corp Lung Biot...,
  
• Ventures Fund Iv General Pa...,
  
• Capital Management, L.P.Abr...,
  
• Merilee Raines,
  
• Capital Management, L.P.Abr...,
  
• Rakesh P. Godhani,
  Chief Digital Officer
• Nicholas Corcoran,
  See Remarks
• Stephanie Lovell,
  
• Anil P. Ranganath,
  See remarks